SWTX — SpringWorks Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.35bn
- $3.05bn
- $191.59m
Annual cashflow statement for SpringWorks Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -45.6 | -174 | -277 | -325 | -258 |
| Depreciation | |||||
| Non-Cash Items | 11.7 | 40.4 | 77 | 101 | 117 |
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.35 | 5.12 | 38.1 | -0.583 | -37.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -32.2 | -128 | -162 | -223 | -176 |
| Capital Expenditures | -0.642 | -2.02 | -10.2 | -7.38 | -20.7 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -418 | 85.6 | -205 | 42.1 | 85.2 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -419 | 83.6 | -216 | 34.8 | 64.5 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 270 | 1.16 | 341 | 297 | 4.76 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -181 | -43.1 | -36.5 | 109 | -106 |